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Abstract
Background: Delirium is a commonly occurring complex
neuropsychiatric disorder. Evidence for its treatment based on
randomized controlled trials (RCTs) is poor. Aims: To determine
the efficacy and acceptability of quetiapine in the treatment of
delirium. Method: A double-blind, RCT was conducted. A total
of 42 patients were randomized to quetiapine or a placebo group.
The primary outcome measure was the Delirium Rating Scale
Revised 98. Other scales used were the Brief Psychiatric Rating
Scale, Mini-Mental State Examination and Clinical Global
Improvement. In order to account for missing data, a nonlinear
mixed-effects model was used to estimate the difference between
the two groups. Results: The quetiapine group improved more
rapidly than the placebo group. Specifically, the quetiapine group

recovered 82.7% faster (S.E. 37.1%, P=.026) than the placebo
group in terms of DRS-R-98 severity score. In terms of the DRSR-98 noncognitive subscale, the quetiapine group improved
57.7% faster (S.E. 29.2%, P=.048) than the placebo group.
Conclusions: Quetiapine has the potential to more quickly reduce
the severity of noncognitive aspects of delirium. This study was
underpowered for treatment comparisons at specific points in time
but nonetheless detected significant differences when analyzing
the whole study period. While it is not possible to draw definitive
conclusions, further larger studies exploring the use of quetiapine
in other delirium populations seem justified. Larger increments in
the dose of quetiapine may yield even stronger results.
© 2010 Elsevier Inc. All rights reserved.
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Delirium is a common disorder that occurs in 11–42% of
general medical inpatients [1] and up to 50% of the
hospitalized elderly [2]. It is a complex neuropsychiatric
syndrome that includes a broad range of cognitive and
noncognitive symptoms. Historically, treatment has focused
on underlying causes. It is also increasingly appreciated that
delirium can be persistent with an independent impact on
functional capacity, morbidity, and mortality. Delirium
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remains understudied, especially in relation to pathophysiology and treatment.
With detection and correction of the underlying cause, the
standard management of delirium includes nonpharmacological and pharmacological treatment [3], but when and what
drugs to use remains uncertain, reflecting a lack of welldesigned efficacy studies. A small open label study suggests
that haloperidol and olanzapine may be effective in the
treatment of delirium [4]. In two RCTs, olanzapine was
recommended as a safe alternative to haloperidol in intensive
care for managing delirium [5,6]. In a case series of 12
patients, quetiapine was found to be beneficial with
improvement shown on Delirium Rating Scale scores along
with improvement in scores of the Mini-Mental State
Examination (MMSE) and Clock Drawing Test [7]. An
open-labeled randomized prospective flexible dosing study
found similar responses for amisulpride and quetiapine [8].
The mean daily dose for the quetiapine group was 113 mg/
day [8]. In a more recent case series of 22 patients, a mean
(S.D.) dose of quetiapine was 45.7 (28.7) mg/day [9].
Prophylactic effects of haloperidol [10] and donepezil
[11] have been studied in placebo-controlled studies as well.
The fluctuating nature of delirium and its potential for
spontaneous recovery as medical problems improve make
placebo-controlled studies especially important in ascertaining the efficacy of drug-treatments.
We report a double blind randomized, placebo-controlled
trial to determine the efficacy and acceptability of
quetiapine in the treatment of incident delirium in general
hospital inpatients with or without minor pre-existing
cognitive deficits.
Methodology
Full ethics committee approval was obtained for this
investigator initiated study to include participants without
mental capacity subject to relative's assent. The South East
Wales Research and Ethics Committee and the Cardiff and Vale
National Health Service (NHS) Trust Research and Development department formally approved the trial. AstraZeneca UK
sponsored the study and provided funding for a research
assistant, trial medication, and the randomization codes.
Sample size calculations indicated that 34 patients in
each treatment group were required to have a 95% power to
detect a mean five-point difference on the Delirium Rating
Scale Revised 98 (DRS-R-98) [12] between the two groups
at the 0.05 confidence level assuming a standard deviation
of 5.6 at a specific time point.
Screening for delirium was conducted by daily contact
with medical, surgical and orthopedic wards at the University
Hospital of Wales by a research assistant. An attempt was
made to recruit those who met the DSM-IV criteria for
delirium on the same day if they had a DRS-R-98 total score
of 15 or more. Individuals with major pre-existing cognitive
deficits, alcohol withdrawal, pre-existing psychosis, substance dependence, inability to comply with the constraints of

the trial, or who were on medication that interacted with
quetiapine were excluded from the study. The nature and
degree of any pre-existing cognitive deficits were determined
by reviewing clinical notes and by obtaining information
from a reliable informant. Informed consent was obtained
from participants with mental capacity.
The DRS-R-98 total mean score was the primary outcome
measure. This score was used to evaluate improvement at
each contact. Secondary outcome measures included the
MMSE, the Brief Psychiatric Rating Scale (BPRS) and the
Clinical Global Improvement (CGI). Tolerability was
assessed by using the Abnormal Involuntary Movements
Scale (AIMS) and clinical examination. The participants
were assessed on Days 1, 2, 3, 4, 7, and 10. A follow-up
assessment was also undertaken on Day 30. Physical status
and investigations were considered at each time point by
reviewing the medical case notes.
After collecting baseline data, participants were blindly
randomized to a flexible dosing regime of 25 mg once daily oral
quetiapine or a matching placebo tablet with dose titration of 25
mg/day to a maximum daily dose of 175 mg in divided doses.
Computer-generated randomization codes were kept in sealed
envelopes at the University Hospital of Wales' Pharmacy. In
addition, a set of individual treatment codes was kept by the
Scottish Poisons Information Bureau, Royal Infirmary Edinburgh, for emergency out-of-hours use only. The dose of
quetiapine was only increased if the DRS-R-98 and clinical
condition did not show any improvement. In addition to the
clinical response and tolerability, information from nursing and
medical staff was also considered prior to dose changes. The
decision to increase the dose was taken by the clinicians
involved in the trial up to a maximum of 10 days after
recruitment. If the treatment was successful and symptoms were
resolved as shown by improvement in the DRS-R-98 and
clinical condition, the dose was down-titrated in the reverse
pattern from initial titration.
To account for the noncompleters, due to various reasons
given below, it was important to take into account missing data
and the improvement in delirium with or without medication;
we used non-linear, mixed-effects model to estimate differences
in recovery trajectories between treatment groups. Initially, we
considered models that allowed different starting and long-term
mean values in the two treatment groups; however, no
significant evidence of such differences was found. The final
models therefore took the form
outcomei ðtÞ ¼ ðf0 þfi Þ þ ðs0 þsi Þ−ðf0 þfi Þ exp−rð1þa xi Þtþei ðtÞ

where s0 is the overall mean starting value; si is a subjectspecific deviation from this starting value for the ith
individual; f0 and fi are the equivalent parameters describing
the overall mean and subject-specific deviation from the
long-term prognosis; t represents the elapsed (calendar) time
from the Day 1 of inclusion in the trial; r describes the rate at
which the placebo group progresses from starting value to
long-term prognosis; xi indicates the treatment group of
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Table 1
Demographic characteristics
Demographic characteristic
Sex: n (%) of patients
Age

Male
Female
Mean (S.D.)
Range

DRS-R-98 b15 n (%) on Day 7
Maximum mean dose of quetiapine (Day 4)
No. of patients prescribed Lorazepam

Quetiapine (n=21)

Placebo (n=21)

Total (n=42)

6 (28.6)
15 (71.4)
84.1 (9.45)
58 to 95
18 (85.7%)
40 mg
4

6 (28.6)
15 (71.4)
84.3 (7.16)
71 to 98
17 (80.9%)

12 (28.6)
30 (71.4)
84.2 (8.28)
58 to 98

subject i; and a describes the difference in recovery rate in the
quetiapine group. If aN0, the quetiapine group recovers more
quickly; if a=0, there is no difference in recovery trajectories,
and if ab0 the quetiapine group recovers more slowly. For
instance, if a=1, then the quetiapine group would recover
twice as quickly as the placebo group.
We reiterate that, following nonsignificant tests of
inequality, the quetiapine and placebo groups were
assumed to have the same mean response at baseline in
all nonlinear models. Note, however, that as the BPRS and
CGI measurements were only made at three time points,
they were not suitable for analysis using non-linear
models. For BPRS and CGI, therefore, the treatment
groups were compared on the three available measurements occasions.

Statistical Package R and SPSS (Version 16) were used
for the analyses.
Results
Between June 2003 and April 2005, 372 patients were
screened to recruit 42 (21 in each group) patients for this
study. Reasons for exclusion were a score less than 15 on
the DRS-R-98, inability to obtain relative's assent,
physical illness of a severity preventing recruitment into
the study, and impairment of mental capacity. Only one
patient was able to consent.
Nineteen of the recruited sample had undergone a surgical
operation. Others had a medical cause for admission. Of the
19 who had surgery, 14 had undergone an orthopedic

Fig. 1. The CONSORT diagram showing patient disposition n (% of total; % of recruited sample).
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Table 2
Mean scores for DRS-R-98 and MMSE for days 1,3 and 10 for quetiapine and placebo groups with mean difference

Day 1

Day 3

Day 10

Variable

Mean quetiapine (S.E.)

Mean placebo (S.E.)

Mean difference

DRS-R-98 Severity
DRS-R-98 total
DRS-R-98 Cognitive
DRS-R-98 Non-cognitive
MMSE
DRS-R-98 Severity
DRS-R-98 Total
DRS-R-98 Cognitive
DRS-R-98 Non-cognitive
MMSE
DRS-R-98 severity
DRS-R-98 Total
DRS-R-98 Cognitive
DRS-R-98 Non-Cognitive
MMSE

19.070 (2.921)
22.736 (3.098)
8.881 (0.995)
10.283 (1.262)
11.829 (4.080)
9.673 (2.647)
11.983 (3.115)
5.796 (0.933)
3.961 (0.735)
16.773 (3.838)
7.132 (3.347)
8.192 (4.223)
4.994 (1.120)
2.391 (0.915)
18.534 (4.757)

19.070 (2.921)
22.736 (3.098)
8.881 (0.995)
10.283 (1.262)
11.829 (4.080)
12.255 (2.204)
14.308 (2.634)
6.419 (0.850)
5.228 (0.698)
16.317 (3.689)
7.387 (3.264)
8.456 (4.133)
5.033 (1.109)
2.465 (0.899)
18.504 (4.739)

0
0
0
0
0
−2.582
−2.325
−0.623
−1.267
−0.456
−0.256
−0.265
−0.04
−0.074
−0.03

procedure; 11, a hip replacement. Many recruited patients had
a number of medical comorbidities, the commonest being
urinary tract infection (5), diabetes (3), atrial fibrillation (3),
and chest infection (2).
The mean (S.D.) age was 84.2 (8.28) years (range 58–98).
All participants were over the age of 65 except for one 58year old. Both groups included 15 females. Sixteen patients
from the quetiapine group and 13 from the placebo group
completed the study (Table 1 and Fig. 1).
The highest mean dose of quetiapine was 40 mg on day 4
(day 1=25 mg, day 10=37.50 mg).
Efficacy of quetiapine
The two groups were not dissimilar in their baseline
scores for DRS-R-98 (Table 2). The mean (S.E.) baseline
total DRS-R-98 scores was 22.736 (3.098) at the start of
the study. Although the total mean DRS-R-98 score tended
to decrease more rapidly for the quetiapine group, no
differences at individual time points reached statistical
significance. On Day 3, mean (S.E.) DRS-R-98 total score
for the quetiapine group was 11.983 (3.115) compared to
14.308 (2.634) for the placebo group. The mean difference
for MMSE scores for Days 3 and 10 were −0.456 and
−0.03 between the quetiapine and the placebo groups
(Table 2).

Table 3
The difference in rate of improvement between quetiapine and placebo
groups for the period of trial
Rate difference between quetiapine
and placebo (S.E., P value)
DRS-R-98
DRS-R-98
DRS-R-98
DRS-R-98

Severity
Total
Cognitive
Non-cognitive

0.827 (0.371, P=.026)
0.55 (0.285, P=.054)
0.572 (0.443, P=.197)
0.577 (0.292, P=.048)

Rate of improvement
The differences in rate of improvement (S.E., P value)
between the two groups for DRS-R-98 total and severity
scores were 0.55 (0.285, P=.54) and 0.827 (0.37, P=.026),
respectively. This suggests that the quetiapine group's
severity scores improved significantly (82%) more quickly
than the placebo group's (Table 3 and Fig. 2).
We further explored the data by dividing DRS-R-98
into noncognitive (Items 1–8) and cognitive (Items 9–13)
subscales. For the trial period, the mean rate difference
(S.E., P value) for improvement for the quetiapine group
in comparison to the placebo group was 0.577 (0.292,
P=.048) and 0.572 (0.443, P=.197) on the noncognitive
and cognitive subscales, respectively. Thus, the quetiapine
group improved significantly (57%) faster than the placebo
group for noncognitive scores (Table 3 and Fig. 2). There
were no significant differences found between treatment
groups for MMSE, BPRS, or CGI Global scores.
Tolerability of quetiapine
Seven patients died within 30 days of entering the study
(four in the quetiapine group and three in the placebo group).
One patient was withdrawn from quetiapine due to
complaints of sedation. No other patients were unable to
tolerate the trial medication. There were low rates of
abnormal involuntary movements in both groups throughout
the 10 days (quetiapine 4.8%; placebo 14.3%).
Dropouts
Apart from seven deaths, other reasons for dropout from the
trial included doctors stopping medication without consultation
with the trial team, patient being nil by mouth for operation,
sedation, patient refusal to comply with medication, and
medication not given by the nursing staff. On review of clinical
information, the deaths were considered to be related to
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Fig. 2. Response to treatment for quetiapine and placebo groups using the non linear mixed effects model.

underlying serious medical conditions including cardiovascular
events rather than the trial medication.

Discussion
This is the first placebo-controlled RCT of quetiapine
in delirium. The trial was stopped early at the request of
the manufacturer due to the Food and Drug Administration's concerns on the use of antipsychotic medication
in the elderly. Even though the study was underpowered
and can be considered a failed study due to the small
sample size, a significantly faster response for quetiapine

was shown on DRS-R-98 severity score. In addition, a
statistically significant improvement in noncognitive items
including restlessness, agitation, thought disorder, and
perceptual impairment on the DRS-R-98 was found on
Day 3 with a mean dose of quetiapine lower than
previously documented, possibly contributed to by the
high mean age of 84 years.
The small sample size is the main limitation of the
study which should be regarded as a pilot study. Strict
inclusion criteria, a high baseline score on the validated
primary outcome measure, use of other validated measures,
information from the case notes to supplement the patient
and nursing staff interviews, homogeneity of subjects, use
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of a flexible dosing regimen, and frequent follow-up to 30
days are strengths in the methodology of this study.
Indeed, a similar methodology has been recommended for
designing clinical trials in this field [13].
Difficulty in recruiting delirium sufferers to treatment
trials is not a new phenomenon. This study had a larger
sample size than any of the RCTs in delirium reviewed by
Boettger and Breitbart [14]. Even with a low dose, these
results are consistent with the findings of previous RCTs of
atypical antipsychotic medication [5,6,8] for delirium and
non-RCT work with quetiapine [7,9]. The results of previous
studies also suggest that low-dose antipsychotic medication
effects improvement in the initial phase of treatment [14-16].
This is important as improvement of delirium is likely to
reduce the distress for patients and their carers and to
potentially reduce inpatient stays.
Despite the inclusion of patients who had pre existing
minor cognitive deficits, quetiapine appeared to be a welltolerated treatment with no evidence of significant adverse
effects such as extra pyramidal side effects, sedation (except
one patient), or cerebrovascular problems.
As delirium can also improve irrespective of treatment
given, the statistical approaches for delirium trials should
take this into account. Instead of comparing group means at
a particular end point, trial reporting should summarize the
whole mean recovery trajectory. Our approach used
nonlinear models to find a trajectory for the recovery
rate. Such nonlinear models with different recovery rates
can be a method to set up an analysis that allows the
hypothesis of equal areas under the mean trajectories to be
statistically tested.
Further studies are now needed with larger samples,
exploration of response predictors, and relationship with
resolution of underlying medical disorder to clarify the role
and safety of antipsychotics in the management of delirium.
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